2
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Heart Diseases
3
Vascular Diseases
2
Small Cell Lung Carcinoma
2
Leukemia, Myeloid, Acute
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Cancer Resectable
1
Ovarian Carcinosarcoma
1
Noonan Syndrome 5
1
Neoplasms, Second Primary
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Metabolic Diseases
1
Liver Neoplasms
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Immune-related Adverse Event
1
Hematologic Neoplasms
1
Heart Failure
1
Esophageal Neoplasms
1
Early Hormone Receptor-positive Breast Cancer
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
Methotrexate
4
sodium thiosulfate
3
Methylprednisolone
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
denileukin diftitox
2
camrelizumab
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
Antineoplastic Agents
×
Clear all
NCT03882580
2023-04-24
NEOCARDIO
Groupe Hospitalier Pitie-Salpetriere
Unknown
5,000 enrolled